134 related articles for article (PubMed ID: 26382309)
1. Comparative efficacy and safety of estradiol transdermal preparations for the treatment of vasomotor symptoms in postmenopausal women: an indirect comparison meta-analysis.
Derzko C; Sergerie M; Siliman G; Alberton M; Thorlund K
Menopause; 2016 Mar; 23(3):294-303. PubMed ID: 26382309
[TBL] [Abstract][Full Text] [Related]
2. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.
Archer DF;
Menopause; 2003; 10(6):516-21. PubMed ID: 14627859
[TBL] [Abstract][Full Text] [Related]
4. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ
Menopause; 2009; 16(1):132-40. PubMed ID: 18971794
[TBL] [Abstract][Full Text] [Related]
5. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
6. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
Simon JA; Bouchard C; Waldbaum A; Utian W; Zborowski J; Snabes MC
Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
[TBL] [Abstract][Full Text] [Related]
7. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women.
Archer DF; Pickar JH; MacAllister DC; Warren MP
Menopause; 2012 Jun; 19(6):622-9. PubMed ID: 22282101
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.
Shulman LP; Yankov V; Uhl K
Menopause; 2002; 9(3):195-207. PubMed ID: 11973443
[TBL] [Abstract][Full Text] [Related]
9. Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data.
Constantine GD; Archer DF; Pollycove R; Jiang W; Altomare C; Pinkerton JV
Menopause; 2016 Sep; 23(9):957-64. PubMed ID: 27404027
[TBL] [Abstract][Full Text] [Related]
10. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial.
Buster JE; Koltun WD; Pascual ML; Day WW; Peterson C
Obstet Gynecol; 2008 Jun; 111(6):1343-51. PubMed ID: 18515518
[TBL] [Abstract][Full Text] [Related]
11. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
[TBL] [Abstract][Full Text] [Related]
12. Low-dose estradiol spray: a novel treatment for vasomotor instability in postmenopausal women.
Buster JE
Womens Health (Lond); 2009 Jan; 5(1):23-8. PubMed ID: 19102636
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints.
von Holst T; Salbach B
Maturitas; 2000 Feb; 34(2):143-53. PubMed ID: 10714909
[TBL] [Abstract][Full Text] [Related]
14. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
15. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
Hattersley G; Harris AG; Simon JA; Constantine GD
Menopause; 2017 Jan; 24(1):92-99. PubMed ID: 27575546
[TBL] [Abstract][Full Text] [Related]
16. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
Rowan JP; Simon JA; Speroff L; Ellman H
Clin Ther; 2006 Jun; 28(6):921-32. PubMed ID: 16860174
[TBL] [Abstract][Full Text] [Related]
17. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review.
Corbelli J; Shaikh N; Wessel C; Hess R
Menopause; 2015 Jan; 22(1):114-21. PubMed ID: 24977458
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
[TBL] [Abstract][Full Text] [Related]
19. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis.
Kovács G; Zelei T; Vokó Z
Climacteric; 2016 Oct; 19(5):488-95. PubMed ID: 27593417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
